Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.

You may also be interested in...



The Era Of Billion Dollar Pharma Settlements

Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.

KV Settles DoJ Complaint Over Claims For Unapproved Drugs; Two Dozen Companies Sued

The $17 million settlement resolves a False Claims Act suit alleging KV’s Ethex subsidiary illegally received reimbursement for two unapproved drugs; at least three other companies have previously settled with the government.

Topamax "Doctor For A Day" Program Drove Off-Label Settlement

J&J's Ortho-McNeil subsidiary pays a criminal fine as part of company's $81 million settlement with the Department of Justice; one doctor made more than $500,000 making office visits with sales reps.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel